Ticker LaunchIPO · CMND
Clearmind Medicine Inc.
Clearmind Medicine Inc. (CMND) priced its initial public offering on Nov 16, 2022 at $6.50 per share, raising $7.5M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $16.1M. Aegis Capital was lead-left underwriter. Greenberg Traurig advised the company and Kaufman & Canoles advised the underwriters.
Clearmind Medicine Inc. is a pre-clinical pharmaceutical company approaching phase 1 trials that develops psychedelic-based medicines. Its goal is new treatments for mental health problems such as alcohol use disorders, binge drinking and eating disorders.
- Status
- IPO
- Ticker
- CMND
- Exchange
- Nasdaq Capital Market
- Priced
- Nov 16, 2022
- IPO price
- $6.50
- Raised
- $7.5M
- Market cap at IPO price
- $16.1M
- First filed
- Jun 29, 2022
- Underwriters
- Aegis Capital
- Company counsel
- Greenberg Traurig
- Underwriters' counsel
- Kaufman & Canoles
- Sector
- Biotech & pharma
- Country / state
- Canada (Federal Level)
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (F-1) first filed Jun 29, 2022
- Latest amendment Nov 14, 2022
- Final prospectus (424B4) Nov 16, 2022
- All filings on EDGAR CIK 1892500
Other Biotech & pharma IPOs in 2022
- Coya Therapeutics, Inc.COYA · Dec 30, 2022 · $15.2M
- Lipella Pharmaceuticals Inc.LIPO · Dec 21, 2022 · $7M
- Acrivon Therapeutics, Inc.ACRV · Nov 16, 2022 · $94.4M
- Prime Medicine, Inc.PRME · Oct 21, 2022 · $175M
- Third Harmonic Bio, Inc.THRD · Sep 15, 2022 · $185.3M
- bioAffinity Technologies, Inc.BIAF · Sep 2, 2022 · $7.9M